Company Overview of Genprex, Inc.
Genprex, Inc. is a clinical-stage biopharmaceutical company. It develops molecular therapies for the treatment of cancer. The company offers Oncoprex, a biologic therapy that targets oncogenic pathways to treat tumors and cancer metastases at the molecular level; and GPRX203 that focuses on solid tumor indications. Genprex, Inc. was formerly known as Convergen LifeSciences, Inc. The company was founded in 2009 and is based in Austin, Texas.
6034 West Courtyard Drive
Austin, TX 78730
Founded in 2009
Key Executives for Genprex, Inc.
Chairman of Scientific & Medical Advisory Board and Key Medical & Scientific Advisor
Strategic Advisor To The Board of Directors
Compensation as of Fiscal Year 2014.
Genprex, Inc. Key Developments
Genprex Begins Phase II Clinical Trial for Lung Cancer
May 20 14
Genprex, Inc. announced that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex(R) in combination with erlotinib (Tarceva(R)) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways. The trial is significant in that it seeks to determine if patients without the EGFR activating mutation as well as patients with the EGFR activating mutation whose cancer has progressed after erlotinib treatment can benefit from the Oncoprex + erlotinib combination therapy. While erlotinib is a blockbuster drug helping many cancer patients worldwide, research shows that the vast majority of patients who have lung cancers without the activating EGFR mutation are unlikely to benefit from erlotinib. Additionally, many patients with the activating EGFR mutation who respond to erlotinib therapy eventually become resistant to the therapy. The Phase II clinical trial evaluates Oncoprex + erlotinib in late-stage lung cancer patients without an activating EGFR mutation who have received prior chemotherapy or in patients with the activating EGFR mutation whose cancer has progressed after treatment with erlotinib. An initial safety and dose-finding portion of the trial tests four escalating doses of the Oncoprex + erlotinib combination. Approximately 40 patients enrolled in the high dose cohort will be evaluable for efficacy.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 20, 2013
December 13, 2013
Most Searched Private Companies
Sponsored Financial Commentaries